CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but.

Slides:

Advertisements

Similar presentations

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Advertisements

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne.

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw

NPM1, IDH1/2 and DNAH11 Gene Mutations Can Improve a Prognostic Stratification of Acute Myeloid Leukemia Patients with Normal Karyotype but Not Harboring.

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Neonatal GATA1 mutant clones under the radar

Defects in DBA: more than meets the eye

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Molecular Cytogenetic Characterization of a Critical Region in Bands 7q35-q36 Commonly Deleted in Malignant Myeloid Disorders by Konstanze Döhner, Jill.

Mutations of Chk2 in primary hematopoietic neoplasms

Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Gupta V, Tallman MS, Weisdorf DJ

Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.

TP53 Mutations In Patients With High-Risk Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation by Jan Moritz Middeke,

Tax fingerprint in adult T-cell leukemia

The V410I (G1228A) variant of the caspase-10 gene is a common polymorphism in the Danish population by Kirsten Grønbæk, Tine Dalby, Jesper Zeuthen, Elisabeth.

Transplants for the elderly in myeloma

Rapid Identification Of Compound Mutations In Patients With Ph-Positive Leukemias By Long-Range Next Generation Sequencing by Sandra Preuner, Renate Kastner,

Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Saman.

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling by.

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with.

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

CMV: when bad viruses turn good

Genetic sequence analysis of inherited bleeding diseases

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

Acute promyelocytic leukemia, microgranular variant

The APC I1307K Allele and BRCA-Associated Ovarian Cancer Risk

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia by Anna Rogers, Youngson.

Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia by Jose Roman-Gomez, Antonio.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia:

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie.

Velizar Shivarov, Lars Bullinger Experimental Hematology

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with.

Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia by Floriana Manodoro, Jacek Marzec, Tracy.

Induced pluripotent stem cell modeling of malignant hematopoiesis

Hotspot Mutation of Brahma in Non-Melanoma Skin Cancer

Validation of Denaturing High Performance Liquid Chromatography as a Rapid Detection Method for the Identification of Human INK4A Gene Mutations Irene.

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission by Sumithira Vasu, Jessica.

Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia by Anne Sophie Kubasch,

by Wendy Lim, Sara K. Vesely, and James N. George

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia by Andrew Wei, Stephen.

A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF ) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic.

Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory.

Diagnostic and Prognostic Implications of Prohibitin Overexpression in Normal Karyotype Acute Myeloid Leukemia by Hye-Ran Kim, Jun Hyung Lee, Min-Gu Kang,

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study by Guillermo Garcia-Manero, Yasmin.

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh,

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

How I treat essential thrombocythemia

Presentation transcript:

CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated withFLT3 internal tandem duplication by David T. Bowen, Marion E. Frew, Sara Rollinson, Philippa L. Roddam, Ann Dring, Martyn T. Smith, Stephen E. Langabeer, and Gareth J. Morgan Blood Volume 101(7):2770-2774 April 1, 2003 ©2003 by American Society of Hematology

Denaturing HPLC profiles from representative AML patient DNA Denaturing HPLC profiles from representative AML patient DNA.(A) Denaturing HPLC profile from DNA containing wild-type codon 12/13 NRAS sequence only. Denaturing HPLC profiles from representative AML patient DNA.(A) Denaturing HPLC profile from DNA containing wild-type codon 12/13 NRAS sequence only. (B) Denaturing HPLC profile from DNA containing wild-type plus mutant sequences. In this profile, wild-type homoduplexes are retained on the dHPLC column for longer (6.36 minutes) than mutant/wild-type heteroduplexes (5.97 minutes). David T. Bowen et al. Blood 2003;101:2770-2774 ©2003 by American Society of Hematology